Sagimet Biosciences prices public offering of 29.2M shares at $6.00/share for ~$164.5M net proceeds

Sagimet Biosciences Inc.

Offering of 29,166,700 shares of common stock at $6.00 per share; net proceeds expected $164.5 million.
Net proceeds to fund Phase 3 trial of denifanstat in acne, TVB-3567 through Phase 2, and topical FASN inhibitor to IND.
Joint book-running managers: Leerink Partners, TD Securities, Guggenheim Securities, and Oppenheimer & Co.
Co-lead managers: Canaccord Genuity, H.C. Wainwright, and JonesTrading.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Sagimet Biosciences Inc. entered into Underwriting Agreement with Leerink Partners LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC as representatives of the several underwriters valued at $164.5 million (effective 2026-04-27).

Action: entry
Agreement: underwriting
Counterparty: Leerink Partners LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC as representatives of the several underwriters
Value: $164.5 million
Effective: 2026-04-27

Exact text from the filing

On April 27, 2026, Sagimet Biosciences Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC as representatives of the several underwriters named therein (the “ Underwriters ”) relating to an underwritten offering (the “ Offering ”) of 29,166,700 shares (the “ Shares ”) of the Company’s Series A common stock, par value $0.0001 per share (the “ Common Stock ”), at an offering price of $6.00 per share.

View on SEC.gov

Browse all material agreements →

Sagimet Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-049756

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.